In #SLE, #HCQ levels >1150 ng/ml ↑toxicity risk w/o added benefit. Levels 750-1150 ng/ml linked to ↓disease activity. CKD stage ≥3 doubled HCQ levels at same dose. Supports monitoring & dose adjustment in CKD to balance safety & efficacy. @RheumNow #EULAR2025 #OP0199

OP0176: Among D2T PsA pts, 43% lacked inflammation on imaging—despite symptoms. Clinical + US split them into PIPsA vs NIPsA, helping distinguish who needs escalation vs who doesn’t. A step toward smarter care in D2T PsA. @RheumNow #EULAR2025 https://t.co/E9igwvDPPN

• https://x.com/JihaRheum/status/1933087629345718777/photo/1

New dual-action RA drug? OP0193: CPL’116 targets both JAK & ROCK. In 12-wk RCT, highest dose improved DAS28-CRP, joint counts & pain, with clean labs. Is this a future option for RA-ILD or patients with comorbid CVD risk? #EULAR2025 @RheumNow

PHOENYCS GO🏃: Dapirolizumab pegol (DZP) led to higher rates of LLDAS (41% vs 20%) & DORIS remission (19% vs 8%) at wk48 vs PBO+SOC. DZP showed earlier & more sustained disease control, advancing T2T in SLE. @RheumNow #EULAR2025 #OP0201 https://t.co/zuxBELxTDd

• https://x.com/DrMiniDey/status/1933088383548420596/photo/1

FAPI-PET/CT - detecting synovial and enthesial fibroblast activation- predicts the development of #psoriatic_arthritis in patients with psoriasis and arthralgia ✨️ A promising tool for early diagnosis of PsA Giulia Corte et al. OP#0174 #EULAR2025 @RheumNow https://t.co/QVmoECIhBI

• https://x.com/Nellziade/status/1933089071397564765/photo/1

Ph 2 RCT CPL'116 dual inhibition JAK/ROCK 106 MTX IR pts wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs. PBO 75% >= AEs, SAE 2: 1 MI, 1 bladder cancer Authors suggest absence of lipids/LFTs disruption compared to other JAKs Ph3 is awaited!! #OP0193 #EULAR2025 https://t.co/TnnM410LfM

• https://x.com/AurelieRheumo/status/1933090354623905889/photo/1
• https://x.com/AurelieRheumo/status/1933090354623905889/photo/1
• https://x.com/AurelieRheumo/status/1933090354623905889/photo/1
• https://x.com/AurelieRheumo/status/1933090354623905889/photo/1

✨️ New Definition Alert The GRAPPA definition of C2M (Complex to Manage) & D2T (Difficult to Treat) #Psoriatic_arthritis A hope for having a homogeneous and widely accepted definition for future clinical research Presented at #EULAR2025 Proft et al. OP#0175 @RheumNow https://t.co/et9cuMROkb

• https://x.com/Nellziade/status/1933091853680648484/photo/1

Combination of LEF and MTX in RA: Yay or Nay? #EULAR2025 @RheumNow

OP0195: MTX+LEF isn’t commonly used—but could it be a viable option after all? In >1,100 RA pts, no link to liver fibrosis (FIB-4/APRI), modest ALT ↑, and fewer hospitalizations. real-world safety data worth a second look. @RheumNow #EULAR2025

OP0179: In a psoriasis cohort, 68% of PsA onset sites showed prior subclinical inflammation (26% tender, 32% US+, 42% both). Should we redefine when PsA truly begins? @RheumNow #EULAR2025

ACQUIVAS: RTX-treated AAV patients had poor response to #pneumococcal vaccine PCV-13 (8% vs 45% in non-RTX). Boosting w/ PPV-23 helped a few but 48% failed to mount robust response. Time to rethink vaccine strategies in RTX-treated patients? @RheumNow #EULAR2025 #OP0173 https://t.co/soU5qfwRib

• https://x.com/DrMiniDey/status/1933097191532585263/photo/1

Premature death in RA still exists, and varies according to race/ethnicity demographic groups Nationwide US CDC's MCoD database analysis -Mortality rates 11x higher American Indians 3x higher Black or African American people -Median age at death with RA 9-10 years younger https://t.co/FTRWPk7Wz0

• https://x.com/AurelieRheumo/status/1933098330000634124/photo/1

#MITIGATE subgroup analysis: Inebilizumab reduced flares & boosted remission across all #IgG4-RD subgroups. HR for flare vs PBO: 0.12-0.16 across sex/race. Similar results for all subgroups in achieving flare-free, treatment-free complete remission. @RheumNow #EULAR2025 #OP0189

RA-related premature mortality highest in American Indians--> 3.6x odds of death in <65 vs White peers, w/ no improvement over 22 yrs. COVID widened the gap. Need to address structural & social drivers of early death in RA, & wider health disparities. @RheumNow #EULAR2025 #OP0197

Yes, it is relevant to ask patients about physical joint strain in RA and propose strain specific interventions In ACPA+ RA pts for each 10% increase in strain, 7% increase in SJC44 and 5% MRI inflammation POS0166 #EULAR2025 @RheumNow https://t.co/jwpi7S8JTW

• https://x.com/AurelieRheumo/status/1933107796003959214/photo/1